VR Adviser’s Protagonist Therapeutics PTGX Stock Holding History

VR Adviser’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-113,140	Closed	-$799K	–	21
2020 Q1	$799K	Buy	+113,140	New	+$848K	0.22%	16

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VR Adviser's PTGX Position: Q2 2020 in Review

VR Adviser sold out of Protagonist Therapeutics (PTGX) in Q2 2020, closing a stake of 113,140 shares — an estimated $799K sold.

VR Adviser first reported a position in PTGX in Q1 2020 and held it in 1 quarter. The position peaked at $799K in Q1 2020. 85 funds tracked by Wall St. Rank hold PTGX as of Q2 2020.

VR Adviser reported no remaining Protagonist Therapeutics position as of Q2 2020 after selling out during the quarter.
VR Adviser sold 113,140 Protagonist Therapeutics shares in Q2 2020, an estimated $799K.
VR Adviser first reported a position in Protagonist Therapeutics in Q1 2020 and held it in 1 quarter.
VR Adviser's Protagonist Therapeutics position peaked at $799K in Q1 2020.
85 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2020.

Based on VR Adviser's 13F filing for Q2 2020, filed 14 Aug 2020.